Maintenance Vitamin D Therapy for Secondary Hyperparathyroidism (2HPT)

计划入组 35 人 · 首次发布于 2009 年 1 月 23 日

Prevalence of Secondary Hyperparathyroidism Among Patients With Diabetic Nephropathy

计划入组 437 人 · 首次发布于 2017 年 5 月 2 日

A Study of SHR6508 in Secondary Hyperparathyroidism

计划入组 75 人 · 首次发布于 2022 年 12 月 23 日

Cinacalcet(Mimpara, Sensipar, Cinacalcet Mylan, Cinacalcet Accordpharma, Cinacalcet Viatris (previously Cinacalcet Mylan), Parareg)

C₂₂H₂₂F₃N · Rx

Etelcalcetide(Parsabiv)

C₃₈H₇₃N₂₁O₁₀S₂ · Rx

Doxercalciferol(Hectorol)

C₂₈H₄₄O₂

Ridgestone Mining Inc

United States

Cornerstone Total Return Fund Inc

iShares Core Composite Bond ETF

United States

Amgen Advances Phase 3 Study of Etelcalcetide for Pediatric Secondary Hyperparathyroidism

Unicycive Submits NDA to FDA for Oxylanthanum Carbonate to Treat Hyperphosphatemia in CKD Patients on Dialysis

FDA Accepts Unicycive's Oxylanthanum Carbonate (OLC) Application for Hyperphosphatemia Treatment